Mallinckrodt Diversifies Hospital Growth Portfolio, Acquiring Three Commercial-Stage, Global Specialty Hemostasis Brands From The Medicines Company — Mallinckrodt will invest in market development of RECOTHROM, PreveLeak™ and RAPLIXA™ – innovative, highly durable hemostasis products that increase surgeons’ choice – — Addition of global hemostasis assets will augment Mallinckrodt’s growing hospital portfolio, including INOmax and THERAKOS; specifically expands on current OFIRMEV surgical pain management offering — — Approved for use in the U.S. and certain European countries with long-range market exclusivity through intellectual property protection – RECOTHROM, 2026; PreveLeak, 2028; RAPLIXA, 2031 — — Upfront payment of approximately $175 million inclusive of existing inventory; transaction also includes potential future added milestone payments and is expected to be financed from cash on hand — –Transaction expected to be accretive in fiscal 2017, driving organic growth for these products in the low double-digits — PR Newswire CHESTERFIELD, United Kingdom, Dec. 18, 2015 CHESTERFIELD, United Kingdom , Dec […]